Learning Objectives:

  1. Define the rare lipodystrphy syndromes and the subtypes.
  2. Show that the observation of low leptin in some patients led to an FDA approved treatment.
  3. Continued work on applying leptin therapy to other metabolic diseases also showed efficacy.


Session date: 
01/23/2017 - 5:00pm to 6:00pm CST
UCMC M-170
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Elif Oral, M.D.